ArticleScientific reports2026
Development and characterization of ivermectin nanoformulations for topical acaricidal activity against Rhipicephalus sanguineus ticks.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ticks are among the most significant ectoparasites of livestock and humans, posing serious health and economic risks. The growing resistance to conventional acaricides highlights the need for safer and more effective alternatives. This study aimed to evaluate the acaricidal efficacy of different ivermectin (IVM) nanoformulations against different developmental stages of Rhipicephalus sanguineus tick. Different ivermectin nanoformulations were fabricated and evaluated for their physicochemical properties. An in vitro study was performed using larval, nymphal, and adult immersion tests, followed by an in vivo trial against unfed adults using the most effective formulation. All nanoformulations showed particle sizes from 450 to 650 nm and a polydispersity index range from 0.34 to 0.65. IVM spanlastics exhibited the smallest particle size, highest encapsulation efficiency (92%), and a sustained release profile. Based on LC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.